|
See related Noxafil oral susp information |
|
|
|
Manufacturer |
MSD |
|
Distributor |
Hong Kong: DKSH/Macau: Four Star |
|
Contents |
Posaconazole |
|
Indications |
Treatment of invasive aspergillosis, fusariosis, chromoblastomycosis & mycetoma, coccidioidomycosis, oropharyngeal candidiasis. Prophylaxis of invasive fungal infections in patients receiving remission-induction chemotherapy & hematopoietic stem cell transplant recipients.
Click to view Noxafil detailed prescribing infomation |
|
Dosage |
Refractory invasive fungal infections (IFI)/intolerant patients w/ IFI 400 mg (10 mL) bds or 200 mg (5 mL) qds. Oropharyngeal candidiasis Loading dose 200 mg (5 mL) once daily on the 1st day, then 100 mg (2.5 mL) once daily 13 days. Prophylaxis of invasive fungal infections 200 mg (5 mL) tds.
Click to view Noxafil detailed prescribing infomation |
|
Overdosage |
View Noxafil overdosage for action to be taken in the event of an overdose. |
|
Administration |
Should be taken with food (Take w/ a meal or w/ a nutritional supplement in patients who cannot tolerate food.). |
|
Contraindications |
Co-administration w/ ergot alkaloids, CYP3A4 substrates & HMG-CoA reductase inhibitors.
Click to view Noxafil detailed prescribing infomation |
|
Special Precautions |
Hypersensitivity to other azoles. Severe hepatic impairment. Patients w/ congenital or acquired QTc prolongation, cardiomyopathy, sinus bradycardia, existing symptomatic arrhythmias, glucose-galactose malabsorption. Monitor liver function tests, potassium, Mg & Ca levels. Pregnancy & lactation. Childn <18 yr.
Click to view Noxafil detailed prescribing infomation |
|
Adverse Drug Reactions |
Neutropenia, electrolyte imbalance, anorexia, paresthesia, dizziness, somnolence, headache, vomiting, nausea, abdominal pain, diarrhoea, dyspepsia, dry mouth, flatulence, elevated liver function tests (eg ALT, AST, bilirubin, alkaline phosphatase, GGT), rash, pyrexia, asthenia, fatigue.
View ADR Monitoring Form |
|
Drug Interactions |
Verapamil, ciclosporin, quinidine, clarithromycin, erythromycin, rifampicin, rifabutin, anticonvulsants, phenytoin, cimetidine, famotidine, ranitidine, omeprazole, terfenadine, astemizole, cisapride, pinozide, halofantrine, ergotamine, dihydroergotamine, simvastatin, lovastatin, atorvastatin, vincristine, vinblastine, tacrolimus, sirolimus, antiretroviral agents, midazolam, triazolam, alprazolam, diltiazem, nifedipine, nisoldipine, digoxin, sulfonylureas.
View more drug interactions with Noxafil |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Noxafil storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Noxafil description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Noxafil mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
ATC Classification |
J02AC04 - posaconazole ; Belongs to the class of triazole derivatives. Used in the systemic treatment of mycotic infections. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
Noxafil oral suspension |
|
Noxafil 40 mg/1 mL x 105 mL |
|
|
|
Manufacturer: |
MSD |
|
Distributor: |
Hong Kong: DKSH
Macau: Four Star |
|
|
|
|
|
